Cardiology Research Institute, Tomsk National Research Medical Center
Aim. To assess the prognostic role of cardiac biomarkers (galectin-3, soluble ST2 (sST2), and N-terminal pro-brain natriuretic peptide (NT-proBNP)) in risk stratification of adverse cardiovascular events (CVEs) in patients with heart failure (HF) after implantation of an automatic implantable cardio...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-08-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4753 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689789168615424 |
|---|---|
| author | E. V. Grakova K. V. Kopyeva A. T. Teplyakov L. K. Isakov M. N. Sinkova N. I. Tarasov |
| author_facet | E. V. Grakova K. V. Kopyeva A. T. Teplyakov L. K. Isakov M. N. Sinkova N. I. Tarasov |
| author_sort | E. V. Grakova |
| collection | DOAJ |
| description | Aim. To assess the prognostic role of cardiac biomarkers (galectin-3, soluble ST2 (sST2), and N-terminal pro-brain natriuretic peptide (NT-proBNP)) in risk stratification of adverse cardiovascular events (CVEs) in patients with heart failure (HF) after implantation of an automatic implantable cardioverter-defibrillator (AICD) within 12-month follow-up period.Material and methods. The study included 57 patients (men, 41; mean age, 65 (59; 68) years) with coronary artery disease and NYHA class II-III HF with left ventricular ejection fraction of 34 [26; 40]%. All patients were implanted with AICD. Serum levels of NT-proBNP, sST2, and galectin-3 were determined by enzyme immunoassay prior to AICD implantation.Results. It has been established that in order to stratify the risk of unfavorable HF in patients after AICD implantation for 12-month follow-up, all three studied biomarkers can be considered as prognostic factors. Thus, an increase in the level of NT-proBNP ≥1046,6 pg/ml (AUC=0,68; p=0,009), sST2 ≥34,43 ng/ml (AUC=0,78; p<0,0001) and galectin-3 ≥11,6 ng/l (AUC=0,72; p=0,0014) predicts a high risk of adverse CVEs. The combination of sST2 and galectin-3 increased the predictive value of the analysis (AUC=0,84; p<0,0001), while the addition of NTproBNP did not increase the accuracy of risk stratification.Conclusion. The determination of the combination of galectin-3 and sST2 can potentially help identify a group of patients with HF after AICD implantation with a high risk of adverse CVEs for intensification and optimization of treatment. |
| format | Article |
| id | doaj-art-0ac858a3ded54e839ab447c31f686ec4 |
| institution | DOAJ |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2022-08-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-0ac858a3ded54e839ab447c31f686ec42025-08-20T03:21:31Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202022-08-0127710.15829/1560-4071-2022-47533492Cardiology Research Institute, Tomsk National Research Medical CenterE. V. Grakova0K. V. Kopyeva1A. T. Teplyakov2L. K. Isakov3M. N. Sinkova4N. I. Tarasov5Cardiology Research Institute, Tomsk National Research Medical CenterCardiology Research Institute, Tomsk National Research Medical CenterCardiology Research Institute, Tomsk National Research Medical CenterKemerovo State Medical UniversityKemerovo State Medical UniversityKemerovo State Medical UniversityAim. To assess the prognostic role of cardiac biomarkers (galectin-3, soluble ST2 (sST2), and N-terminal pro-brain natriuretic peptide (NT-proBNP)) in risk stratification of adverse cardiovascular events (CVEs) in patients with heart failure (HF) after implantation of an automatic implantable cardioverter-defibrillator (AICD) within 12-month follow-up period.Material and methods. The study included 57 patients (men, 41; mean age, 65 (59; 68) years) with coronary artery disease and NYHA class II-III HF with left ventricular ejection fraction of 34 [26; 40]%. All patients were implanted with AICD. Serum levels of NT-proBNP, sST2, and galectin-3 were determined by enzyme immunoassay prior to AICD implantation.Results. It has been established that in order to stratify the risk of unfavorable HF in patients after AICD implantation for 12-month follow-up, all three studied biomarkers can be considered as prognostic factors. Thus, an increase in the level of NT-proBNP ≥1046,6 pg/ml (AUC=0,68; p=0,009), sST2 ≥34,43 ng/ml (AUC=0,78; p<0,0001) and galectin-3 ≥11,6 ng/l (AUC=0,72; p=0,0014) predicts a high risk of adverse CVEs. The combination of sST2 and galectin-3 increased the predictive value of the analysis (AUC=0,84; p<0,0001), while the addition of NTproBNP did not increase the accuracy of risk stratification.Conclusion. The determination of the combination of galectin-3 and sST2 can potentially help identify a group of patients with HF after AICD implantation with a high risk of adverse CVEs for intensification and optimization of treatment.https://russjcardiol.elpub.ru/jour/article/view/4753heart failureadverse cardiovascular eventsimplantable cardioverterdefibrillatorbiomarkersgalectin-3prognosis |
| spellingShingle | E. V. Grakova K. V. Kopyeva A. T. Teplyakov L. K. Isakov M. N. Sinkova N. I. Tarasov Cardiology Research Institute, Tomsk National Research Medical Center Российский кардиологический журнал heart failure adverse cardiovascular events implantable cardioverterdefibrillator biomarkers galectin-3 prognosis |
| title | Cardiology Research Institute, Tomsk National Research Medical Center |
| title_full | Cardiology Research Institute, Tomsk National Research Medical Center |
| title_fullStr | Cardiology Research Institute, Tomsk National Research Medical Center |
| title_full_unstemmed | Cardiology Research Institute, Tomsk National Research Medical Center |
| title_short | Cardiology Research Institute, Tomsk National Research Medical Center |
| title_sort | cardiology research institute tomsk national research medical center |
| topic | heart failure adverse cardiovascular events implantable cardioverterdefibrillator biomarkers galectin-3 prognosis |
| url | https://russjcardiol.elpub.ru/jour/article/view/4753 |
| work_keys_str_mv | AT evgrakova cardiologyresearchinstitutetomsknationalresearchmedicalcenter AT kvkopyeva cardiologyresearchinstitutetomsknationalresearchmedicalcenter AT atteplyakov cardiologyresearchinstitutetomsknationalresearchmedicalcenter AT lkisakov cardiologyresearchinstitutetomsknationalresearchmedicalcenter AT mnsinkova cardiologyresearchinstitutetomsknationalresearchmedicalcenter AT nitarasov cardiologyresearchinstitutetomsknationalresearchmedicalcenter |